213 related articles for article (PubMed ID: 29137895)
1. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
[TBL] [Abstract][Full Text] [Related]
2. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H
BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251
[TBL] [Abstract][Full Text] [Related]
3. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
[TBL] [Abstract][Full Text] [Related]
5. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
6. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
7. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.
Kim EH; Andriole GL; Crawford ED; Sjoberg DD; Assel M; Vickers AJ; Lilja H
J Urol; 2017 Apr; 197(4):1041-1047. PubMed ID: 27810449
[TBL] [Abstract][Full Text] [Related]
8. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
10. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H
Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522
[TBL] [Abstract][Full Text] [Related]
11. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
12. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
[TBL] [Abstract][Full Text] [Related]
13. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
[TBL] [Abstract][Full Text] [Related]
14. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781
[TBL] [Abstract][Full Text] [Related]
15. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H
J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547
[TBL] [Abstract][Full Text] [Related]
16. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
Benchikh A; Savage C; Cronin A; Salama G; Villers A; Lilja H; Vickers A
BMC Cancer; 2010 Nov; 10():635. PubMed ID: 21092177
[TBL] [Abstract][Full Text] [Related]
17. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
18. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
Carlsson SV; Peltola MT; Sjoberg D; Schröder FH; Hugosson J; Pettersson K; Scardino PT; Vickers AJ; Lilja H; Roobol MJ
BJU Int; 2013 Sep; 112(5):602-9. PubMed ID: 23448270
[TBL] [Abstract][Full Text] [Related]
19. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
[TBL] [Abstract][Full Text] [Related]
20. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume.
Vertosick EA; Zappala S; Punnen S; Hugosson J; Boorjian SA; Haese A; Carroll P; Cooperberg M; Bjartell A; Lilja H; Vickers AJ
Urology; 2021 Nov; 157():102-106. PubMed ID: 34450175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
